Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Epilepsy NMEs: A View Of The Playing Field

Executive Summary

The late-stage pipeline for novel epilepsy treatments stars a handful of specialty and foreign firms, but the early-stage lineup makes room for new firms and the products of academic research. Venture philanthropy is a big factor, but the poor funding climate for CNS firms may limit play.


Related Content

UCB's Keppra Follow-On Briviact Gains FDA Nod For Epileptic Seizures
Supernus Set To Launch Trokendi XR Against Generic Topamax
With New Mechanism, Can Eisai’s Fycompa Make Its Mark In Epilepsy?
Eisai Wins FDA Approval For Novel, Once-Daily Seizure Drug Fycompa
Specialty Pharma Dominates Epilepsy Market, But Does It Have Resources To Develop Disease-Modifying Agents?
Belgium's UCB Is Almost Over Its Patent Cliff, But Guides Revenues And Profits To Decline In 2012
Top Partnering Opportunities In Neuroscience: The Ugly Truth
GSK/Valeant's Potiga Gets REMS, Needs DEA Classification For Launch
Lamictal XR's Monotherapy Claim May Spur More Historical Control Trials
Venture Philanthropy: The New Venture Capital?


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts